Pharmacology I Theory Notes

Overview

This chapter introduces the core principles of pharmacodynamics - how drugs produce effects at the level of molecules, cells, and tissues. You will learn about drug-receptor interactions, the shapes of dose-response relationships, types of drug action (agonists, antagonists, partial agonists), and common mechanisms by which drugs change physiological processes. Visual diagrams are described to help you picture binding, efficacy, potency, and competitive versus noncompetitive antagonism. Worked examples tie concepts to calculations and interpretation of dose-response curves. By the end you should be able to explain why two drugs with the same target can have different effects and predict how changing dose or receptor number alters response.

Study tips for this chapter:

• Sketch receptor-ligand binding as a lock-and-key and add labels for affinity and occupancy.
• Draw simple dose-response curves and mark EC50 and maximal effect.
• Practice interpreting shifts caused by competitive and noncompetitive antagonists.

Core Content

Drug-receptor interactions

• Receptors are proteins (membrane-bound or intracellular) that transduce drug binding into a biological response. Think of the receptor as the “effector switch.” Key properties:
• Affinity: how tightly a drug binds to the receptor. Higher affinity means less drug is needed to occupy receptors.
• Intrinsic activity (efficacy): the ability of a bound drug to activate the receptor and produce a response.
• Diagram: draw receptors in a membrane, show Drug A (high affinity) and Drug B (low affinity) binding; annotate that more B is needed to occupy the same fraction of receptors.

Agonists, antagonists, and partial agonists

• Full agonist: high efficacy; can produce maximal response when it occupies receptors.
• Partial agonist: binds receptors but produces less than maximal activation, even when all receptors are occupied. Acts as an agonist in absence of full agonist and can act as a functional antagonist in its presence.
• Antagonist: binds receptors without activating them; blocks agonist action.
• Competitive antagonist: binds reversibly to the same site as agonist. On a dose-response curve, it shifts the curve to the right (higher concentration needed) without reducing maximal effect if antagonist concentration is not too high.
• Noncompetitive antagonist: reduces maximal effect by either irreversible binding or blocking downstream signaling; curve shows decreased maximal response.

Dose-response relationships

• Graded dose-response: relationship between dose and continuous measure of effect in a single individual or preparation. Key parameters:
• EC50: concentration producing 50% of maximal effect; a measure of potency.
• Emax: maximal effect; a measure of efficacy.
• Quantal dose-response: population-based (all-or-none outcomes, e.g., seizure prevention). Used to calculate ED50 (dose effective in 50% of population) and therapeutic index.
• Worked example: drug X has EC50 = 2 mg/L, drug Y has EC50 = 0.5 mg/L, both same Emax. Y is more potent (less drug needed), but both can reach same maximal effect.

Receptor reserve and spare receptors

• Some tissues have more receptors than needed to produce maximal response. This “receptor reserve” means partial occupancy can still yield full effect - important for potency and effects of irreversible antagonists.
• Visual: show three levels of receptor occupancy (low, medium, high) with same maximal response if reserve exists.

Mechanisms of drug action beyond receptors

• Enzyme inhibition or activation (e.g., ACE inhibitors block angiotensin-converting enzyme).
• Ion channel modulation (e.g., local anesthetics block sodium channels).
• Transporter blockade (e.g., SSRIs block serotonin reuptake).
• Receptor modulation is most common in pharmacodynamics, but remember drugs can act indirectly by altering ligand synthesis, release, or degradation.

Interpreting dose-response graphs quickly

• Right shift, same Emax: competitive antagonism or reduced potency.
• Downward shift in Emax: noncompetitive antagonism or loss of efficacy.
• Lower EC50 (left shift): increased potency, possibly due to higher affinity or increased receptor number.

Study support

• Practice by sketching three curves: control, with competitive antagonist, with noncompetitive antagonist. Label EC50 and Emax differences.
• Flashcards: definitions of affinity, efficacy, EC50, ED50, therapeutic index.
• Quick-check question: If a drug’s maximal effect falls after adding a second compound, is that likely competitive or noncompetitive antagonism? (Answer: noncompetitive.)

Summary

Pharmacodynamics explains how drugs interact with biological targets to produce effects. Core ideas: affinity (binding strength), efficacy (ability to produce response), and potency (EC50). Agonists activate receptors; antagonists block them; partial agonists occupy an intermediate role....